

London, 17 December 2009 Doc.Ref. EMA/CHMP/818349/2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE POST-AUTHORISATION SUMMARY OF POSITIVE OPINION* for BONVIVA

International Nonproprietary Name (INN): Ibandronic acid

On 17 December 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion** to recommend the variation to the terms of the marketing authorisation for the medicinal product Bonviva. The Marketing Authorisation Holder for this medicinal product is Roche Registration Ltd.

The CHMP adopted a new contraindication for Bonviva 150 mg film-coated tablets as follows:

- "- Abnormalities of the oesophagus which delay oesophageal emptying such as stricture or achalasia
- Inability to stand or sit upright for at least 60 minutes"

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full contraindications for Bonviva 150 mg film-coated tablets will be as follows **** :

- "- Abnormalities of the oesophagus which delay oesophageal emptying such as stricture or achalasia
- Inability to stand or sit upright for at least 60 minutes
- Hypocalcaemia
- Hypersensitivity to ibandronic acid or to any of the excipients.

See also section 4.4."

The text in bold represents the new or the amended contraindication.

^{*} Summaries of positive opinion are published without prejudice to the Commission Decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the Opinion.

^{**} Marketing Authorisation Holders may request a re-examination of any CHMP opinion, provided they notify the EMEA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.